ArticleFrontiers in oncology2022
Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Delta radiomics: an updated systematic review.La Radiologia medica · 2024Pooled it
- Early prediction of immune checkpoint inhibitor-related pneumonitis in advanced non-small cell lung cancer based on primary tumor delta-radiomics features.Frontiers in immunology · 2026Article
- Quantification of head and neck cancer patients' anatomical changes during radiotherapy: Toward the prediction of replanning need.Journal of applied clinical medical physics · 2026Article
- Early toxicity prediction using longitudinal cone-beam CT delta-radiomics in HPV-positive oropharyngeal cancer.Frontiers in oncology · 2026Article
- Integrating CT Radiomics and Clinical Information to Predict Prognosis of Advanced NSCLC Patients Receiving Chemoimmunotherapy.Current medical science · 2025Article
- Multimodal integration of longitudinal noninvasive diagnostics for survival prediction in immunotherapy using deep learning.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- Comparison of MRI Sequences to PredictBiomedicines · 2024Article
- Review
- Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer.Frontiers in immunology · 2024Review
- MRI-based intratumoral and peritumoral radiomics for preoperative prediction of glioma grade: a multicenter study.Frontiers in oncology · 2024Article
- Radiomics based onFrontiers in oncology · 2024Article
- Developing a novel dosiomics model to predict treatment failures following lung stereotactic body radiation therapy.Frontiers in oncology · 2024Article
- Delta-radiomics in cancer immunotherapy response prediction: A systematic review.European journal of radiology open · 2023Article
- Radiomics nomogram for the prediction of Ki-67 index in advanced non-small cell lung cancer based on dual-phase enhanced computed tomography.Journal of cancer research and clinical oncology · 2023Article
- Radiomic biomarkers from chest computed tomography are assistive in immunotherapy response prediction for non-small cell lung cancer.Translational lung cancer research · 2023Article
- Article
- Gender Medicine in Clinical Radiology Practice.Journal of personalized medicine · 2023Review
- Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the validity of pre- and posttreatment computed tomography (CT)-based radiomics signatures and delta radiomics signatures for predicting progression-free survival (PFS) in stage III-IV non-small-cell lung cancer (NSCLC) patients after immune checkpoint inhibitor (ICI) therapy. Methods: Quantitative image features of the largest primary lung tumours were extracted on CT-enhanced imaging at baseline (time point 0, TP0) and after the 2 Results: The C-index of TP0, TP1 and delta radiomics models in the training and validation cohort were 0.64, 0.75, 0.80, and 0.61, 0.68, 0.78, respectively. The delta radiomics score exhibited good accuracy for distinguishing patients with slow and rapid progression to ICI treatment. The predictive accuracy of the combined prediction model was higher than that of the clinical prediction model in both training and validation sets (P<0.05), with a C-index of 0.83 and 0.70, respectively. Additionally, the delta radiomics model (C-index of 0.86) had a higher predictive accuracy compared to PD-L1 expression (C-index of 0.50) (P<0.0001). Conclusions: The combined prediction model including clinicopathologic characteristics (tumour anatomical classification and brain metastasis) and the delta radiomics signature could achieve the individualized prediction of PFS in ICIs-treated NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.